Pentamaster (PENT MK)






Pentamaster (PENT MK): Marching into stronger 2H25


Pentamaster (PENT MK)

Marching into stronger 2H25

MALAYSIA | TECHNOLOGY | RESULT

P PhillipCapital
  • 2Q25 core net profit was in line with ours and consensus estimate
  • Management is upbeat on 2H25, expecting a rebound in ATE demand as semiconductor customers resume capex
  • We downgrade the stock to HOLD albeit with a higher TP of RM3.57

2Q25 core earnings declined 14% YoY

2Q25 revenue declined 16% YoY to RM145m, mainly due to lower contributions from the Factory Automation Solutions (FAS) segment. The medical segment saw a sharp 54% YoY drop, while the automotive segment declined 14% YoY, both impacted by demand normalization following a strong expansion in the prior year. After stripping out the RM7m forex loss, RM5m employees’ share scheme and RM1m PIL delisting costs, core net profit stood at RM20m (+44% QoQ, -14% YoY), accounting for 45% of our and 46% street’s full-year forecasts. The result is in line with our expectations, in anticipation of stronger 2H25 earnings.

6M25 core net profit within expectations

6M25 core net profit declined 29% YoY to RM34m, due to the weaker medical segment, but was partially offset by stronger contributions from consumer/industrial and semiconductor segments. The group’s renewable energy segment also began contribution during the quarter. Pentamaster’s order book remained stable QoQ at RM350m, with FAS accounted for 65% of the total (50% medical, 13% consumer/industrial, 2% electro-optical, 1% renewable energy). The remaining 35% was from the ATE segment, led by automotive (19%) and semiconductor (15%).

Downgrade to HOLD with a higher TP of RM3.57

We raise our 12-month target price to RM3.57, pegged to a target PE of 28x on 2026E EPS (based on its updated -1.5SD its 3-year mean; from 25x or -1.5D its 5-year mean previously). Management anticipates stronger earnings momentum in 2H25, supported by better ATE demand outlook, citing a recovery in semiconductor capex as customers resume capex in the next-generation test handling and burn-in systems. We downgrade the stock to HOLD as the recent 34% share price rally has priced in near-term upside with a more balanced risk-reward profile. Key risks to our call include sharp appreciation of RM versus US$, better/lower-than-expected margins, and customer orders.

Key Financials

Y/E Dec 2023 2024 2025E 2026E 2027E
Revenue (RMm) 691.9 623.0 672.9 699.8 727.8
EBITDA (RMm) 139.8 129.2 122.9 145.7 152.5
Pretax profit (RMm) 128.5 105.4 109.2 129.5 142.5
Net profit (RMm) 76.2 65.2 76.0 90.7 102.0
EPS (sen) 10.7 9.2 10.7 12.7 14.3
PER (x) 34.7 40.6 34.8 29.2 25.9
Core net profit (RMm) 86.8 79.7 76.0 90.7 102.0
Core EPS (sen) 12.2 11.2 10.7 12.7 14.3
Core EPS growth (%) 18.0 (8.2) (4.7) 19.3 12.5
Core PER (x) 30.5 33.2 34.8 29.2 25.9
Net DPS (sen) 2.0 2.0 2.0 3.0 3.0
Dividend Yield (%) 0.5 0.5 0.5 0.8 0.8
EV/EBITDA (x) 17.6 19.6 20.8 17.5 16.5
Chg in EPS (%)
Phillip/Consensus (%) 1.03 1.02 0.99

Results at a glance

Y/E Dec (RMm) 2Q24 1Q25 2Q25 QoQ % chg YoY % chg 6M24 6M25 YoY % chg YoY Comment
Revenue 171.4 131.6 144.9 10.1 (15.5) 342.2 276.5 (19.2) Driven by higher contribution from FAS segment, particularly medical segment
Op costs (133.2) (104.3) (113.2) 8.5 (15.1) (266.3) (217.5) (18.3)
EBITDA 38.1 27.3 31.7 16.1 (16.9) 75.9 59.0 (22.2)
EBITDA margin (%) 22.3 20.8 21.9 1.1ppt (0.4ppt) 44.3 42.6 (1.7ppt)
Depreciation (5.3) (6.8) (7.0) 3.4 33.7 (10.3) (13.9) 33.9
EBIT 32.9 20.5 24.7 20.3 (25.0) 65.5 45.2 (31.1)
EBIT margin (%) 19.2 15.6 17.0 1.4ppt (2.2ppt) 38.3 32.6 (5.7ppt)
Interest Income 2.6 1.6 1.6 (0.1) (36.5) 6.0 3.3 (44.9)
Associates (0.0) (0.8) (0.3) (65.4) 793.3 (0.3) (1.0) 313.5
Exceptional items (3.4) (0.8) (8.4) n.m n.m (8.4) (9.2) n.m Mainly consist of RM7m forex loss, RM5m PIL employees share scheme, RM1m delisting expenses for PIL
Pretax profit 32.1 20.6 17.6 (14.1) (45.0) 62.9 38.2 (39.3)
Core pretax profit 35.4 21.4 26.0 21.8 (26.5) 71.2 47.4 (33.4)
Taxation (0.5) (0.3) (0.3) 1.8 (28.8) (1.0) (0.7) (32.0)
Tax rate (%) 1.3 1.5 1.3 (0.3ppt) (0.0ppt) 2.7 2.8 0.1ppt
MI (11.7) (7.2) (5.7) (20.3) (51.3) (22.6) (12.9) (43.2)
Net profit 19.9 13.1 11.6 (11.1) (41.7) 39.3 24.7 (37.2)
EPS (sen) 2.8 1.8 1.6 (11.1) (41.7) 5.5 3.5 (37.2)
Core net profit 23.2 13.9 20.0 44.0 (14.0) 47.6 33.9 (28.9) In line with ours and consensus expectation

Segmental Revenue & PBT Breakdowns

Segmental Revenue Breakdown (Y/E Dec, RMm)

2Q24 1Q25 2Q25 QoQ % chg YoY % chg 6M24 6M25 YoY % chg
ATE 69.8 95.8 82.7 (13.7) 18.5 142.6 178.5 25.2
FAS 101.5 35.8 61.2 70.9 (39.8) 199.4 97.0 (51.4)
Smart Solution 0.0 0.0 (0.0) n.m n.m 0.1 (0.0) n.m
Adjustments 0.0 0.0 1.0 n.m n.m 0.0 1.0 n.m
Total 171.4 131.6 144.9 10.1 (15.5) 342.2 276.5 (19.2)

Segmental PBT Breakdown (Y/E Dec, RMm)

2Q24 1Q25 2Q25 QoQ % chg YoY % chg 6M24 6M25 YoY % chg
ATE 4.2 24.5 9.3 (61.9) 122.4 15.8 33.8 113.5
FAS 33.8 4.5 16.6 264.0 (51.0) 57.4 21.1 (63.2)
Smart Solution (1.0) 0.1 (0.1) n.m n.m (1.5) (0.0) n.m
Adjustments (4.9) (8.5) 8.5 n.m n.m (8.8) 0.0 (100.0)
Total 32.1 20.6 34.3 66.9 6.9 62.9 54.8 (12.8)

Segmental PBT Margin (Y/E Dec)

2Q24 1Q25 2Q25 QoQ ppt YoY ppt 6M24 6M25 YoY % chg
ATE 6.0 25.5 11.3 (14.3ppt) 5.3ppt 22.0 36.8 67.5
FAS 33.3 12.7 27.1 14.3ppt (6.2ppt) 57.4 39.8 -30.7
Total 18.7 15.6 23.7 8.1ppt 4.9ppt 36.8 39.3 6.9

Segmental Revenue Breakdown by Sub-segment (Y/E Dec, RMm)

2Q24 1Q25 2Q25 QoQ % chg YoY % chg 6M24 6M25 YoY % chg
Automotive 51.4 51.0 44.1 (13.6) (14.3) 95.3 95.1 (0.2)
Medical 77.0 6.9 35.6 416.7 (53.8) 155.5 42.5 (72.7)
Semiconductor 11.5 26.4 11.9 (54.7) 3.9 21.3 38.3 79.9
Consumer/industrial 6.8 20.3 16.9 (16.6) 149.6 16.9 37.3 120.3
Electro-optical 24.7 26.8 32.8 22.3 32.9 53.0 59.6 12.3
Renewable Energy 0.0 0.0 3.6 n.m n.m 0.0 3.6 n.m
Others 0.0 0.2 (0.0) n.m n.m 0.1 0.2 67.9
Total 171.4 131.6 144.9 10.1 (15.5) 342.2 276.5 (19.2)

Important disclosures

This research report is strictly confidential and has been prepared for information purposes only by Phillip Research Sdn Bhd (“PRSB”), a subsidiary of Phillip Capital Holdings Sdn Bhd (“PCH”) and is meant for circulation to its clients and clients of other subsidiaries companies of PCH particularly Phillip Mutual Berhad (“PMB”), Phillip Capital Management Sdn Bhd (“PCM”), Phillip Wealth Planners Sdn Bhd (“PWP”) and Phillip Capital Sdn Bhd (“PCSB”) (collectively refer to as Phillip Group other licensed intermediaries (“PGOLI”)) only or such other persons as may be deemed eligible to receive such research report, information or opinion contained herein. Neither the publication/communication nor any portion hereof may be reprinted, distributed, sold, resold, redistributed, copied, reproduced, published, republished, displayed, posted or transmitted in any form or media or by any means without the written consent of PRSB.

PRSB Investment and Sector Definition:

BUY: Total stock return expected to exceed +10% over 12-month period

HOLD: Total stock return to be between -10% and +10% over a 12-month period

SELL: Total stock return is expected to below 10% over a 12-month period

OVERWEIGHT: The sector is expected to outperform the overall FBMKLCI over the next 12 months

NEUTRAL: The sector is to perform in line with the overall FBMKLCI market over the next 12 months

UNDERWEIGHT: The sector is expected to underperform the overall FBMKLCI market over the next 12 months

The information, opinions and estimates herein are not directed at, or intended for distribution to or use by, any person or entity in any jurisdiction where doing so would be contrary to law or regulation or which would subject PRSB and/or its associate companies to any additional registration or licensing requirement within such jurisdiction. The information and statistical data herein have been obtained from sources we believe to be reliable. Such information has not been independently verified and we make no representation or warranty as to its accuracy, completeness or correctness. Any opinions or estimates herein reflect the judgment of PRSB at the date of this publication/communication and are subject to change at any time without notice. This is not a solicitation or any offer to buy or sell. This publication/communication is for information purposes only and does not constitute any recommendation, representation, warranty or guarantee of performance.


Leave a Reply

Your email address will not be published. Required fields are marked *